In this article, we identify the 13 Best Multibagger Stocks to invest in now.
The global economic and geopolitical environment in 2025 is marked by uncertainty, trade tensions, and shifting monetary policies. According to an article published by the CFA Institute citing the IMF, the United States remains resilient, with growth projected at 2.7%, while global GDP growth is at 3.3% in 2025.
In April, Reuters reported that the US and China paused their trade war. An agreement saw the U.S. cut its tariff rate from 145% to 30%, while China reduced its tariffs from 125% to 10%, for a period of 90 days. The stock markets climbed in reaction to these developments, reflecting investor optimism about easing trade tensions. Meanwhile, the fed rate remains between 4.25% and 4.50%, with no immediate plans for cuts, as mentioned by Fed Chair Jerome Powell.
Investors can capitalize on market volatility by investing in multibagger stocks. These are stocks that multiply in value several times over a short period, delivering returns far beyond the initial investment, building on their strong fundamentals, innovative business models, and significant expansion potential. Multibagger stocks present compelling growth prospects, particularly in volatile economic environments.
Our Methodology
We scanned the FinViz market screener to identify stocks that had a price of less than $20. We then filtered them for stocks that had a growth potential greater than 200% over the next twelve months, based on a consensus of analysts following these stocks. Our rankings are from lowest to highest based on their upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
13. Savara Inc. (NASDAQ:SVRA)
Upside Potential: 212.84%
Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company dedicated to addressing the unmet needs of patients suffering from rare respiratory diseases. Founded in 1995, Savara is a key player in this niche field through innovative therapeutic development and a commitment to delivering life-changing solutions to patients worldwide. The company focuses on diseases that have limited treatment options, ensuring its research has a significant impact on improving health outcomes.
The cornerstone of Savara Inc. (NASDAQ:SVRA) current pipeline is MOLBREEVI, a promising therapeutic designed to treat autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease characterized by the accumulation of surfactant in the alveoli, impeding gas exchange and leading to respiratory distress. MOLBREEVI is currently undergoing Phase 3 clinical trials and has already demonstrated notable improvements in gas exchange, as well as measurable clinical benefits for patients. Savara is actively pursuing regulatory approval through a rolling Biologics License Application (BLA) submission to the FDA, and it is preparing for a Marketing Authorization Application (MAA) to the European Medicines Agency. These efforts reflect Savara’s commitment to bringing MOLBREEVI to market as efficiently as possible.
Unlike many biopharmaceutical companies, Savara employs a unique business model that emphasizes outsourcing the majority of its clinical development and manufacturing activities to specialized vendors and consultants. This approach enables the company to operate in a capital-efficient manner, maximizing resources while maintaining the highest standards of quality and innovation. Additionally, Savara’s leadership team has extensive experience in navigating the complexities of drug development and commercialization, further strengthening its strategic position in the industry.
Financially, Savara Inc. (NASDAQ:SVRA) is in a strong position, with approximately $196 million in cash and short-term investments as of its latest financial report. This robust financial reserve ensures the company’s operations remain funded through Q2 2027, providing a solid foundation for advancing its pipeline and achieving its goals. Analysts have expressed optimism about Savara’s prospects, citing the company’s growing momentum, innovative pipeline, and prudent investment strategy as key drivers of its twelve-month average price target of $9.44, which reflects a substantial upside potential of 212.84%.
12. Aquestive Therapeutics, Inc. (NASDAQ:AQST)
Upside Potential: 245.96%
Aquestive Therapeutics (NASDAQ:AQST) stands out as a dynamic pharmaceutical company that has carved a distinct niche in the field of drug delivery innovation. Founded in 2004 in Warren, New Jersey, the company specializes in developing and commercializing advanced drug delivery systems designed to improve both absorption and patient convenience. Its flagship PharmFilm technology represents a groundbreaking approach to medication administration. Thin, dissolvable films created through this technology can be used sublingually (under the tongue), buccally (inside the cheek), or lingually (on the tongue), offering an alternative to traditional tablets or injections. This innovation not only enhances ease of use but also ensures faster and more reliable delivery of active ingredients, making it particularly beneficial for patients with difficulty swallowing or those requiring rapid onset of treatment.
Aquestive has leveraged its PharmFilm technology to build an impressive portfolio of FDA-approved treatments that address critical health conditions. Among its notable products are Libervant, designed to manage seizures; Sympazan, which provides relief for individuals with Lennox-Gastaut syndrome, a severe form of epilepsy; and Suboxone, a treatment aimed at combating opioid dependence. The company’s unique ability to merge pharmaceutical expertise with convenience-centric solutions has enabled it to establish a robust patent portfolio. Aquestive’s collaborations with leading pharmaceutical firms further cement its position in the global market, ensuring its innovative therapies reach a wider audience and bring meaningful improvements to patients’ lives.
Financially, Aquestive continues to demonstrate resilience and potential for growth. In the fourth quarter of 2024, the company reported revenues of $11.87 million, reflecting a year-over-year decline of 10.14%, but its full-year revenue of $55.2 million underscores steady progress in its proprietary PharmFilm technology. With secure cash reserves of $65.1 million, Aquestive is well-positioned to advance its drug pipeline and pursue ambitious research and development goals. Analysts remain optimistic about its prospects, forecasting a twelve-month average share price of $9.86, representing a remarkable upside potential of 245.96%. Aquestive Therapeutics is undoubtedly poised for significant advancements in the pharmaceutical industry.
11. Rezolute, Inc. (NASDAQ:RZLT)
Upside Potential: 260.32%
Rezolute, Inc. (NASDAQ:RZLT) is a late-stage biopharmaceutical company focused on addressing rare diseases, particularly those involving hypoglycaemia caused by hyperinsulinism. Incorporated in 2010 and originally known as AntriaBio, Inc., it officially changed its name to Rezolute, Inc. in 2017.
Rezolute’s main product candidate, ersodetug (formerly known as RZ358), is a treatment for congenital hyperinsulinism (cHI), a rare genetic disorder in children, and is currently in Phase 3 clinical trials. The company is also working on RZ402, a pill that targets diabetic macular edema (DME), which is now undergoing Phase 2 testing.
Rezolute, Inc.’s (NASDAQ:RZLT) unique value proposition lies in its development of ersodetug, a promising therapeutic option that aims to address rare diseases such as congenital hyperinsulinism. Unlike competitors who focus primarily on inhibiting insulin secretion, Rezolute’s approach offers a potentially universal solution for these complex conditions. This strategic differentiation is further bolstered by regulatory advantages, including Orphan Drug and Rare Pediatric Disease designations, which underline its commitment to addressing unmet medical needs.
Building on this momentum, Rezolute recently achieved a significant milestone when its Chief Medical Officer, Brian Roberts, announced the Independent Data Monitoring Committee’s (DMC) favorable recommendation for continuing the Phase 3 sunRIZE study as planned. Roberts expressed optimism, stating:
“We are thrilled with the DMC’s favorable recommendation, which appears to validate our initial assumptions for the design and powering of the Phase 3 sunRIZE study.”
In terms of the company’s financial standing, Rezolute has secured $120 million in financing, ensuring robust support for the late-stage development of RZ358, its lead candidate for congenital hyperinsulinism. This financial strength underscores its readiness to advance research and development efforts. With 70% of analysts assigning a buy rating to the stock and a consensus average price target of $13.44 for the next twelve months, Rezolute presents an upside potential of 260.32%.
10. Altimmune, Inc. (NASDAQ:ALT)
Upside Potential: 288.54%
Altimmune, Inc.(NASDAQ:ALT) is a clinical-stage biopharmaceutical company. It focuses on developing treatments for obesity, metabolic, and liver diseases. ALT’s lead product/candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist, which is currently in clinical development for the treatment of obesity and metabolic associated steatohepatitis (MASH).
The mechanism of action for pemvidutide involves the activation of GLP-1 and glucagon receptors, aiming to mimic the effects of diet and exercise on weight loss. This includes suppressing appetite and increasing energy expenditure, while also impacting hepatic fat metabolism, potentially leading to reductions in liver fat and serum lipids. Over 500 subjects have been involved in clinical trials for pemvidutide, showcasing a favorable safety profile and significant clinical benefits. Altimmune is leveraging the differentiated clinical profile of pemvidutide to pursue additional indications, beyond obesity and MASH.
In terms of the company’s financial performance, Altimmune, Inc.’s (NASDAQ:ALT) first quarterly earnings report for 2025 revealed a modest revenue of $5,000, but still higher than forecasts. Chief Executive Officer, Vipin Garg, spoke during the earnings call on the company’s investment in infrastructure to support its key product, pemvidutide. He stated:
“We announced today that we have entered into a credit facility with Hercules Capital for up to $100 million. This is strategically important as we build upon our balance sheet strength and provide flexibility to support our continued development of pemvidutide.”
Investors raised concerns about the company’s lack of cash holdings which stood at $150 million at the end of the first quarter. However, the $100 million injection mentioned by the CEO offers a ray of hope. Analysts on Wall Street following the stock continue to hold an optimistic opinion about the company’s potential. Altimmune, Inc.’s (NASDAQ:ALT) is estimated to have an average twelve-month trading price of $22.38 based on analysts’ consensus, an upside of 288.54%.
9. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Upside Potential: 285.81%
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company with a pioneering approach to gene science-based medicines. It focuses on developing therapies for neuropathic pain and cardiometabolic diseases, addressing critical unmet medical needs. Lexicon employs precision science to create innovative treatments that aim to significantly improve patient lives. Among its notable products is Sotagliflozin, marketed under the brand name INPEFA, which is specifically designed to reduce cardiovascular risks such as heart failure and type 2 diabetes. This drug represents a substantial advancement in the management of complex cardiovascular conditions.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) distinguishes itself through its unique focus on creating orally-delivered small molecule drugs. These therapies are specifically engineered to target diseases in a way that enhances convenience and accessibility for patients. The company is committed to developing treatments that not only improve health outcomes but also simplify the treatment process for individuals grappling with debilitating conditions. Additionally, Lexicon has fostered strategic collaborations with renowned entities like Viatris Inc. and Bristol-Myers Squibb. These partnerships aim to bolster its drug development capabilities while extending its reach into specialized markets. The company’s collaborative efforts enhance its ability to innovate and deliver differentiated therapeutic options in highly competitive fields.
A testament to its success and strategic decisions, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) latest earnings report for Q1 of 2025 highlighted a revenue of $1.26 million (11.68% higher YoY), surpassing analyst estimates. Over the course of the financial year 2024, the company generated an impressive $97.3 million in revenue, largely driven by the commercial sales of INPEFA, its flagship heart failure treatment. Analysts on Wall Street remain cautiously optimistic, with 50% recommending a “Hold” strategy for the stock. However, the consensus average share price over the next twelve months is projected to be $2.60, offering an upside potential of 285.81%.
8. Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)
Upside Potential: 285.81%
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is a clinical-stage biopharmaceutical company dedicated to pioneering innovative treatments for brain health disorders. With a focus on addressing the therapeutic needs of patients suffering from anxiety, depression, autism spectrum disorders, and other severe mental health challenges, MindMed explores the promising potential of psychedelics and other compounds. The company’s approach is rooted in cutting-edge research, aiming to develop transformative solutions that improve patients’ quality of life by targeting the underlying mechanisms of these disorders.
A key candidate in MindMed’s pipeline is MM120, a proprietary form of lysergide D-tartrate. This compound has gained considerable attention for its potential efficacy in treating generalized anxiety disorder (GAD) and major depressive disorder (MDD). Currently in Phase 3 clinical trials, MM120 has shown remarkable promise in addressing symptoms of anxiety and depression. Preliminary results from earlier trials indicate a rapid onset of therapeutic effects, with the benefits enduring for at least 12 weeks without requiring adjunct psychotherapy. This durability and reliability have positioned MM120 as a groundbreaking candidate in the realm of mental health treatments.
MindMed’s financial stability bolsters its ability to advance clinical programs efficiently. The company reported a strong cash position of $273 million, ensuring a robust financial runway to sustain operations and progress its trials. During the first quarter of 2025, CEO Rob Barrow reaffirmed MindMed’s commitment to furthering its clinical programs, specifically emphasizing the pivotal Phase 3 trials for MM120 ODT. These trials, named Voyage, Panorama, and Emerge, are strategically designed to refine the therapeutic applications of MM120, aiming to deliver comprehensive solutions for GAD and MDD. Top-line results from these trials are eagerly anticipated by 2026, which could mark a significant milestone in the field of mental health treatment.
With a solid cash balance of $245.5 million as of March 31, 2025, MindMed remains well-equipped to operationally sustain its progress through 2027. Analysts on Wall Street have expressed optimism regarding the company’s growth trajectory, projecting a twelve-month average share price of $24.50, offering an upside potential of 291.37%.
7. AbCellera Biologics Inc. (NASDAQ:ABCL)
Upside Potential: 474.37%
AbCellera Biologics Inc. (NASDAQ:ABCL) is an AI-powered biotechnology company specializing in antibody discovery. Founded in 2012, the company integrates cutting-edge technology, advanced data science techniques, and interdisciplinary expertise to streamline the development of innovative antibody medicines. These medicines target a range of health issues, including cancer, autoimmune disorders, and metabolic conditions, addressing critical therapeutic needs in the biopharmaceutical landscape. AbCellera’s pipeline includes promising candidates such as ABCL635, designed to tackle metabolic and endocrine conditions, and ABCL575, which is focused on treating T-cell-mediated autoimmune conditions like atopic dermatitis. Both programs remain in preclinical stages, with Clinical Trial Applications expected to commence by 2025, a milestone that underscores AbCellera’s commitment to advancing its pipeline with precision and speed.
AbCellera’s success has been bolstered by strategic collaborations with industry giants such as Eli Lilly, Biogen, and AbbVie. These partnerships have enabled the company to leverage partner insights, cutting-edge technologies, and shared expertise to develop highly optimized clinical candidates. Since its inception, AbCellera has initiated an impressive 96 partner programs, with 16 molecules having reached clinical trials, a testament to the effectiveness of its unique platform. The company’s focus extends beyond partnerships, as it has heavily invested in its research infrastructure. By the end of 2025, AbCellera aims to complete its clinical manufacturing facilities, a significant step that will position the company to efficiently bring next-generation antibody therapeutics to market while maintaining high standards of innovation and quality.
In terms of financial performance, AbCellera Biologics Inc. (NASDAQ:ABCL) demonstrated a solid topline of $4.24 million for the first quarter of 2025, bolstered by milestone payments and antibody discovery collaborations. For the full year 2024, the company reported a topline of $28.8 million, further solidifying its financial robustness. With a substantial cash position of $540 million, AbCellera is well-equipped to sustain its growth trajectory. On 15th May, 2025, analysts downgraded their estimates based on revenue estimates being lower than expectations. Overall, however, analysts remain optimistic about the stock, highlighting an average share price projection of $11.43 over the next twelve months, presenting an upside potential of 474.37%.
6. aTyr Pharma, Inc. (NASDAQ:ATYR)
Upside Potential: 485.17%
aTyr Pharma, Inc. (NASDAQ:ATYR) stands as a pioneering biotherapeutics company dedicated to discovering and developing innovative medicines targeting novel immunological pathways. Established in 2005, aTyr Pharma has carved out a niche in addressing the critical needs of patients suffering from interstitial lung diseases (ILDs), a group of disorders characterized by progressive scarring of lung tissues. Among its promising initiatives, the company’s lead therapeutic candidate, Efzofitimod, has emerged as a beacon of hope. Efzofitimod, a selective modulator of neuropilin-2 (NRP2), holds the potential to transform the treatment landscape for ILDs. Currently undergoing Phase III clinical trials, as well as Phase 1b/2a trials, Efzofitimod is designed to reduce inflammation and improve lung function, offering a possibility of reducing or even eliminating the need for corticosteroids, a significant advancement for patients who endure long-term side effects from these standard therapies.
The company’s commitment to advancing Efzofitimod has been bolstered by its strategic partnership with Kyorin Pharmaceutical Co., Ltd. This collaboration focuses on Efzofitimod’s development and commercialization in Japan, enabling aTyr Pharma to leverage Kyorin’s established presence and resources within the Japanese market while simultaneously concentrating its efforts on operations in the United States. Such global partnerships underscore aTyr Pharma’s forward-thinking approach to expanding its reach and ensuring the accessibility of its groundbreaking treatments.
In addition to its clinical endeavors, aTyr Pharma, Inc. (NASDAQ:ATYR) has a robust cash position of $88 million that provides a solid foundation for continued innovation and expansion. Analysts are optimistic about the stock, with 63% recommending it as a “Strong Buy” and the remainder holding a “Buy” position. Reflecting this confidence, the consensus amongst analysts pegs the average share price at $18.55 over the next twelve months, marking an upside potential of 485.17%.
5. Perspective Therapeutics, Inc. (NYSE:CATX)
Upside Potential: 460.47%
Perspective Therapeutics, Inc. (NYSE:CATX), a biotechnology company specializing in precision-targeted alpha therapies (TAT) for cancer treatment, has steadily carved a niche in the realm of oncology. Initially founded in 1998 as Isoray, Inc., the company underwent a transformative rebranding in February 2023, following its merger with Viewpoint Molecular Targeting, Inc. This strategic move has strengthened its positioning in the competitive biotech landscape, enabling it to focus on developing innovative solutions for some of the most challenging cancer types.
The company’s primary drug candidates demonstrate its commitment to precision medicine. VMT-α-NET, currently in Phase 1/2a clinical trials, targets neuroendocrine tumors with precision, offering hope for patients battling these often difficult-to-treat malignancies. Additionally, PSV359 aims to address fibroblast activation protein alpha, further showcasing Perspective Therapeutics’ diverse therapeutic approach. By employing an integrated theranostic model (combining diagnostics and therapeutics), the company effectively delivers targeted radiation to cancer cells while minimizing harm to surrounding healthy tissue. This innovative method exemplifies its dedication to enhancing treatment efficacy and patient outcomes.
Perspective Therapeutics’ strategic collaborations are the cornerstone of it’s business model. CATX’s partnership with Bristol Myers Squibb to evaluate the safety and tolerability of VMT01, used alongside nivolumab for melanoma patients, highlights the company’s focus on leveraging leading-edge research to advance its clinical programs. Furthermore, its manufacturing and supply capabilities, developed across facilities in Iowa and New Jersey, underpin both ongoing clinical trials and potential commercial-scale operations. The organization also maintains global development rights for its promising candidates, ensuring flexibility and control throughout its pipeline. Perspective Therapeutics works closely with prominent academic institutions such as the University of Iowa and Mayo Clinic, fostering innovation and scientific rigor in its research. Leveraging partnerships, advanced technology, and strategic growth initiatives, the company is poised to make significant strides in oncology.
A recent filing reveals that in March of 2025, Graham Juan, Chief Financial Officer of Perspective Therapeutics, Inc. (NYSE:CATX), reportedly made a notable investment in the company’s common stock. The report shows that Mr. Juan acquired 33,333 shares at a weighted average price of approximately $2.25 per share, totaling $74,945. The purchase comes as the stock hovers near its 52-week low, having fallen over 83% in the past year. Analysts on Wall Street have taken notice, with 93% expressing optimism regarding the stock’s future performance. As of May 13, 2025, the consensus among analysts places the twelve-month projected share price at $14.32, signifying an impressive upside potential of 460.47%. This outlook reflects growing confidence in Perspective Therapeutics’ ability to deliver transformative treatments to patients worldwide.
4. Capricor Therapeutics, Inc. (NASDAQ:CAPR)
Upside Potential: 489.89%
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a biotechnology company that specializes in developing cell and exosome-based therapies for muscular and other diseases. Its flagship therapeutic candidate, CAP-1002, is in advanced clinical stages and is designed to address Duchenne muscular dystrophy (DMD), a severe genetic disorder that primarily affects muscles and the heart. CAP-1002 utilizes cardiosphere-derived cells (CDCs), which have been shown to modulate the immune system and reduce harmful tissue buildup, known as fibrosis, in the heart. This unique approach underscores the company’s dedication to tackling complex medical conditions through innovative science.
In addition to its work on CAP-1002, Capricor is actively advancing its exosome platform, which harnesses the potential of extracellular vesicles for therapeutic applications. Collaborations with esteemed institutions such as the National Institutes of Health (NIH), the U.S. Army Institute of Surgical Research, Johns Hopkins University, and Cedars-Sinai Medical Center exemplify its commitment to advancing research and development. These partnerships aim to broaden the scope of Capricor’s initiatives, including the development of vaccines and therapeutics for infectious diseases and monogenic disorders.
Capricor Therapeutics has demonstrated financial strength and strategic foresight. For the fourth quarter of 2024, the company reported revenues of $11.13 million, contributing to a total of $25.4 million in annual revenue. This growth is attributed to its pioneering efforts in cell therapy programs. With $78 million in cash reserves, Capricor is well-equipped to support ongoing clinical trials and future commercialization efforts, ensuring sustainability in its ambitious endeavors.
In March, Reuters reported in an article Capricor Therapeutics (CAPR.O) announced that the U.S. Food and Drug Administration (FDA) intends to assemble a panel of external experts to review its cell therapy for a heart condition associated with Duchenne muscular dystrophy (DMD) before making a final decision. The company is pursuing full regulatory approval for its investigational cell therapy, deramiocel, as a potential treatment for patients with Duchenne muscular dystrophy cardiomyopathy. Following the news, the company’s shares dropped nearly 15%, reaching $10.11 in morning trading. Wall Street analysts, however, have taken a favorable view of Capricor’s prospects, recommending the stock as a “Strong Buy.” The consensus twelve-month price target as of May 13, 2025, stands at $43.71, reflecting a remarkable upside potential of 489.89%.
3. Autolus Therapeutics plc (NASDAQ:AUTL)
Upside Potential: 697.60%
Autolus Therapeutics plc (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company specializing in the development of T-cell therapies for the treatment of cancer and autoimmune diseases. Established in 2014, Autolus is advancing innovative approaches in the field of chimeric antigen receptor (CAR) T-cell therapy, aiming to transform patient outcomes with cutting-edge science and technology.
Autolus has strategically positioned itself to meet global demand through its dedicated commercial manufacturing facility, known as “The Nucleus,” located in the UK. This facility not only supports clinical and commercial production requirements but also ensures scalability and flexibility, enabling the company to cater to expanding markets. Autolus retains worldwide commercial rights to its products and maintains a focused marketing strategy targeting key regions such as the United States, the United Kingdom, and Europe. This strategic approach highlights the company’s commitment to delivering transformative therapies across diverse geographic markets while ensuring the highest standards of quality in production.
Further analysis of the company’s business model and financial performance reflect its significant progress in advancing CAR T-cell therapy. In the first quarter of 2025, Autolus posted revenue of $9 million, demonstrating steady growth. For the full year of 2024, the company reported $45.8 million in revenue, driven by its pioneering efforts in cancer treatment development. With $210 million in cash reserves, Autolus is well-positioned to support the commercialization plans for its therapies and sustain future research and development endeavors. This financial stability has contributed to a positive outlook among analysts, who project the company’s share price to reach $9.97 within the next twelve months, offering an upside potential of 697.60%. Through its relentless pursuit of innovation and financial health, Autolus Therapeutics plc remains at the forefront of oncology treatment, pushing boundaries and redefining possibilities in CAR T-cell therapy.
2. Larimar Therapeutics, Inc. (NASDAQ: LRMR)
Upside Potential: 957.52%
Larimar Therapeutics, Inc. (NASDAQ:LRMR) is a biotechnology company focused on developing innovative treatments for rare genetic disorders. Among its pioneering efforts is the development of Nomlabofusp (CTI-1601), a therapeutic candidate specifically designed to address Friedreich’s ataxia (FA). This rare and progressive genetic disorder stems from insufficient levels of frataxin, a mitochondrial protein essential for proper cellular function. By delivering frataxin to affected cells, Nomlabofusp aims to target the core deficit of FA, offering hope for improved cellular health and a potential slowing of disease progression.
Central to Larimar’s scientific approach is its proprietary intracellular delivery platform. This technology enables therapeutic molecules to cross cell membranes effectively, opening new possibilities for addressing other rare diseases marked by similar deficiencies or intracellular dysfunctions. The company continues to explore and expand its pipeline, leveraging this platform to address unmet needs in the realm of rare diseases. This forward-thinking strategy positions Larimar as a leader in developing transformative therapies in the biotechnology sector.
In December of last year, the company disclosed that two patients experienced serious adverse events related to its experimental therapy, nomlabofusp, a treatment for Friedreich’s ataxia (FA. This lead to a decline in the company’s share price by 30% in intra-day trading. Larimar Therapeutics, however, maintains a strong financial foundation. The company’s Q1 2025 earnings report highlighted its solid financial position with $157.5 million in cash, cash equivalents, and marketable securities as of March 31, 2025. This financial stability provides the resources necessary to sustain research and development activities and bolster commercialization efforts. Furthermore, Larimar projects its cash runway to extend well into the second quarter of 2026, ensuring continued progress in its clinical programs.
Analysts have taken note of Larimar’s promising trajectory, expressing confidence in the company’s potential for growth. With an upside of 957.52%, the stock’s estimated twelve-month price projection stands at $20.04, reflecting optimism about the potential impact of the company’s groundbreaking work. Through its innovative technologies, strategic focus, and financial resilience, Larimar Therapeutics is advancing solutions that may redefine the treatment of rare diseases for patients worldwide.
1. Jasper Therapeutics, Inc. (NASDAQ:JSPR)
Upside Potential: 914.02%
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company that focuses on developing therapeutics targeting mast and hematopoietic stem cell-driven diseases. Its lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells.
JSPR focuses on the development and commercialization of therapeutic agents for patients with various mast cell-driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency.
In terms of marketing and distribution, Jasper Therapeutics, Inc. (NASDAQ:JSPR) has established exclusive licensing agreements with Amgen and Stanford University for the development and commercialization of briquilimab. These collaborations are crucial for advancing the company’s product candidates and expanding its research capabilities. The company stated on its website:
“We have an exclusive license agreement with Amgen Inc. (“Amgen”) for the development and commercialization of the briquilimab monoclonal antibody in all indications and territories worldwide.”
It must be noted that Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported a net loss of $21.2 million for the first quarter of 2025, which was significantly higher than the previous year. This reflects increased operating expenses, primarily in research and development. The company’s cash balance stands at $49.2 million as of March 31, 2025. Meanwhile, operating expenses were higher at $15.1 million, with research and development expenses rising from $10.3 million to $16.2 million, both on a year-on-year comparison. Ronald Martell, President and Chief Executive Officer of Jasper spoke on the company’s performance:
“During the first quarter of 2025 we made great progress advancing briquilimab toward important data readouts later this year from all three of our clinical programs in mast cell diseases”.
On May 15, 2025, Oppenheimer analyst Jay Olson issued an update on Jasper Therapeutics (JSPR, Financial), reaffirming the firm’s ‘Outperform’ rating for the company but revising the price target. Analysts on Wall Street following the stock hold an optimistic view of the company, with a “Strong Buy” rating and a consensus on the average price for the next twelve months estimated at $49.89, an upside of $4.92.
Overall, Jasper Therapeutics, Inc. (NASDAQ:JSPR) ranks 1st on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of JSPR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JSPR and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy.
Disclosure. None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
